Micralax

Quick links to important sections

Micralax

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micralax

Quick Facts

Property Description
Active Ingredients Sodium Citrate, Sodium Lauryl Sulfoacetate
Form Rectal Micro-enema (Solution)
Pharmacological Class Laxative / Bowel Evacuant
General Purpose Symptomatic relief of occasional constipation
Origin Synthetic (Chemically manufactured)

What Type of Medicine is Micralax?

Micralax is a proprietary combination preparation classified within the general therapeutic group of laxatives and the specific pharmacological class of bowel evacuants. This synthetic liquid formulation is administered as a rectal micro-enema, which is a distinguishing feature that allows for local administration directly into the lower bowel. The drug is intended to provide predictable symptomatic relief for acute instances of occasional difficulty with passing stool. Unlike oral tablets, this method of delivery is clinically recognized for achieving effect rapidly due to the targeted application. The product is officially classified under the Anatomical Therapeutic Chemical (ATC) code A06AG11, which designates enemas containing sodium lauryl sulfoacetate, often in combinations.

Composition: Sodium Citrate and Sodium Lauryl Sulfoacetate

The preparation contains two primary active ingredients: Sodium Citrate (or Trisodium citrate) and Sodium Lauryl Sulfoacetate, dissolved in an aqueous solution base. The component Sodium Citrate functions primarily as an osmotic agent, helping to draw water into the rectal area, a key action for softening dry stool. The second component, Sodium Lauryl Sulfoacetate, is chemically characterized as a surfactant and wetting agent. This dual-agent composition combines a salt and a wetting agent to facilitate the breakdown and lubrication of hardened stool. This combination is utilized for its focused action, such as preparing the lower bowel for specific procedures.

Micralax’s General Purpose and Action

The general purpose of the rectal micro-enema is to facilitate prompt and comfortable bowel evacuation. By utilizing the osmotic effect and surfactant action locally, the medicine ensures effective stool softening and lubrication. This physical modification of the stool, combined with the resultant stimulation of the natural defecation reflex, helps to reduce the physical strain and discomfort associated with passing hard, compacted stools. This combination product is optimized for its non-systemic approach, focusing entirely on the immediate resolution of local retention.

What side effects are possible with Micralax?

Possible Side Effects and Safety Information

The official safety profile for the micro-enema containing Sodium Citrate and Sodium Lauryl Sulfoacetate is characterized by adverse reactions that are predominantly local to the administration site, alongside a documented potential for systemic immune reactions. According to regulatory documentation, the frequency for most reported adverse reactions is classified as Not known, as estimation is not possible from available post-marketing data.

System-Organ Classifications of Adverse Effects

Adverse effects listed in official labeling are grouped under:

  • Gastrointestinal Disorders: These are related to the site of administration and include local symptoms such as rectal discomfort, a burning sensation, or local pain.
  • Immune System Disorders and Skin and Subcutaneous Tissue Disorders: These encompass the possibility of hypersensitivity reactions, including the manifestation of urticaria (hives).

Safety Restrictions and Duration

Contraindications in regulatory labeling strictly prohibit the use of this medicine in individuals with a known hypersensitivity to the active ingredients. Use is also restricted for patients with certain pre-existing inflammatory bowel conditions, such as active ulcers or inflammation of the large bowel.

A key safety pattern noted in regulatory documents is the warning against prolonged or continuous use of laxatives, which may lead to the risk of dependence and local anal canal irritation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for this rectal micro-enema addresses situations involving excessive use of the product, noting that overdosage is generally unlikely due to its localized route of administration. The focus is on the documented effects that may arise from using amounts greater than recommended.


Documented Overdose Manifestations

Presentation Cause Management Strategy
Diarrhoea Excessive Use Symptomatic Treatment
Fluid Loss Excessive Use Supportive Care

The official prescribing information does not list severe or life-threatening systemic outcomes linked to the use of this specific product. No specific antidote is known or documented in the regulatory labeling.


Emergency Response and Required Action

If the product is used in excessive amounts or more than recommended, official documents mandate that an individual seek medical advice immediately. This action is required to ensure appropriate guidance and management of the resulting clinical manifestations.

Required actions include contacting a healthcare professional (doctor) or the local poison control center for advice. Management of these documented consequences is strictly supportive, focusing on the appropriate symptomatic treatment of fluid loss, in line with established clinical guidelines. Regulatory authorities require these steps be taken without delay following excessive exposure.

Therapeutic Uses of Micralax

What Micralax Treats: Main Uses and Benefits

Micralax is relevant for easing symptoms related to physical discomfort across specific therapeutic domains related to lower bowel function, and may assist with maintaining functional stability.

The preparation is commonly used to help with acute rectal constipation and to support clearance before procedures such as X-ray examination or rectoscopy. The primary therapeutic areas of use are relevant for easing symptoms related to acute rectal constipation, supporting clearance before diagnostic tests, and assisting patients with circumstantial retention.

Key Therapeutic Domains

This medication is relevant for easing symptoms related to physical discomfort in situations where patients experience difficulty passing stool, and is commonly used across conditions presenting with acute episodes of rectal constipation. It supports the patient during difficult episodes by easing distress by addressing symptom clusters that include straining and the feeling of hard stool retention. Micralax is considered relevant in clinical settings where short-term symptomatic assistance is needed to support bowel preparation for specific procedures, and is applied across domains where additional symptomatic support is needed for patient groups like the elderly or those with limited mobility.


Quick Fact: Relief for Localized Retention

Benefit Focus Context of Use Symptoms Addressed
Symptomatic Relief Acute, temporary constipation Difficulty passing stool, Straining
Functional Support Clinical preparation, Limited mobility Hard stool retention, Incomplete evacuation

Regulatory References

  1. NIH DailyMed Drug Label Information

Eligibility and Restrictions for Use

Who can and cannot use Micralax?

The official eligibility for Micralax use is defined by specific regulatory categories, focusing on age and contraindications related to bowel health and hypersensitivity.

Populations for whom use is contraindicated:

Category Contraindication
Allergy Known hypersensitivity to sodium citrate, sodium lauryl sulfoacetate, or any excipients.
Bowel Health Patients with Inflammatory Bowel Disease (IBD).

Age-Related Eligibility:

Micralax is approved for use in adults and children aged 3 years and over. Use in children under 3 years of age is permitted but comes with a specific regulatory restriction requiring that the administration nozzle be inserted only half its length.

Conditional Use and Special Populations:

The medicine requires extreme caution if used in patients with ulcerative or inflammatory conditions of the large bowel.

Pregnancy and Lactation:

Official labeling generally considers occasional use acceptable during both pregnancy and lactation due to the product’s local action and minimal systemic absorption. Consultation with a healthcare professional is advised before use in these populations.

What should I know about interactions with other medicines?

Micralax Interactions with other medicines and products

Official regulatory information regarding Micralax (Sodium Citrate and Sodium Lauryl Sulfoacetate micro-enema) indicates a minimal interaction profile, which is consistent with its localized, non-systemic route of administration and minimal absorption.


Formally Documented Contraindication

Only one significant interaction is explicitly documented in regulatory prescribing information, classified as a formal contraindication:

Classification Interacting Substance Description of Risk
Contraindicated Combination Sodium Polystyrene Sulphonate Risk of intestinal necrosis when co-administered (rectally or orally). This is due to the presence of the excipient Sorbitol in Micralax.

Absence of Systemic Interactions

Official government labels do not document interaction statements for several common categories, reflecting the non-systemic nature of the product. This means:

  • Pharmacokinetic Interactions: No interactions affecting metabolic enzymes (such as CYP450) or drug transporters are documented.
  • Exposure Modification: No substances are listed that increase or decrease the plasma levels ( AUC or C max) of the active ingredients.
  • Timing Separation: No mandatory timing separation rules are documented for administering Micralax with other medicines.
  • Non-Medicinal Interactions: No restrictions or warnings regarding interactions with food, alcohol, or herbal products are included in the official prescribing information.

Mechanism of Action

Micralax's action is defined by a swift, local physico-chemical mechanism that alters the physical state of the impacted stool rather than modulating systemic physiological pathways.


Fecal Dehydration Reversal via Peptisation

This core domain explains how the active ingredients modify the stool's composition. Sodium Citrate functions as a peptising agent, initiating an ion-exchange reaction to displace and release water molecules that are chemically bound within the hardened fecal mass. This action locally reverses the dehydration of the stool, increasing the free water content within the rectum, which establishes the necessary conditions for the overall mechanism.


Synergistic Wetting and Penetration

This domain addresses the crucial role of the combination's components in accelerating the process. Sodium Lauryl Sulfoacetate acts as a surfactant, lowering the interfacial surface tension between the solution and the stool to facilitate rapid and deep penetration of the water-releasing agents. This synergy promotes a swift and thorough softening process, facilitating the initiation of the evacuation mechanism.


Mechanical Activation of the Defecation Reflex

This final domain explains the physiological consequence of the modification. The rapid softening, liquefaction, and resulting increase in stool volume mechanically distends the pressure receptors in the rectal wall. This stimulus initiates the natural defecation reflex pathway, triggering the smooth muscle contractions (peristalsis) necessary for subsequent clearance of the modified fecal matter.

Dosage and Administration Information

How to Use Micralax: Official Administration Guidelines

Micralax is administered exclusively via the rectal route as a solution contained within a single-dose micro-enema tube. The formulation contains Sodium Citrate 450 mg and Sodium Lauryl Sulfoacetate 45 mg in a 5 mL unit dose. The medicine is intended for occasional, short-term use and should not be used for prolonged or regular treatment, establishing its use as an intermittent intervention.


Standard Dosing and Frequency

Instruction Detail
Standard Dose The complete contents of one micro-enema tube (5 mL).
Frequency Pattern As-needed; administered as a one-time dose per occasion of need.

Age-Specific Administration Rules

While the dose remains one tube for most patients, the procedural technique varies for the youngest population. For adults and children aged 3 years and over, the standard full-nozzle insertion technique is used. For children under 3 years, instructions specify inserting only half the length of the nozzle into the rectum. No specific dose modifications are mandated for other populations, such as during pregnancy or lactation.


Procedural Context

Administration involves preparing the nozzle tip by squeezing out a small drop of the solution for lubrication. Following full dose delivery, the nozzle must be withdrawn while the tube is kept squeezed tightly to ensure the entire dose is retained. The onset of action is generally expected to occur within 5 to 30 minutes after application. These guidelines define a standardized protocol for the administration of this locally acting preparation.

Recent Clinical Evidence

Research Evidence for Acute Rectal Constipation

Studies explored the micro-enema in research contexts involving temporary or episodic changes in constipation symptoms. These clinical trials and comparative studies evaluated this localized approach alongside other laxative forms and was studied for outcomes related to physical discomfort and the time required for a bowel movement to occur. The studies monitored the time interval for an observed bowel movement and gathered patient-reported outcomes describing perceived discomfort and ease of use.

Despite the available evidence, data remain insufficient to provide insight into managing long-term or chronic constipation. Follow-up durations were limited, focusing exclusively on the immediate, acute action.


Research Evidence for Pre-Procedural Bowel Preparation

The micro-enema was evaluated in a research context where a localized clearance of the lower bowel is needed for procedures like rectoscopy. Historical clinical trials and comparative studies examined the method’s use. Research explored the quality of preparation achieved and the time required to achieve that status before the procedure. Studies observed whether the product was associated with outcomes related to procedural preparation quality. Comparative evidence appears to be limited for its use as the primary agent for more extensive procedures like a full colonoscopy.


Research in Specific Patient Groups

Studies explored the micro-enema in different patient groups, with data show patterns related to use in children (including infants) and older adults. Research has also examined its application in pregnant and postnatal women, where outcomes monitoring physiological strain or stress were assessed. Data for certain groups remain insufficient to draw broad conclusions, and subgroup findings are uncertain when trying to generalize beyond the immediate, acute management context.


Long-Term Studies and Evidence Gaps

The micro-enema was studied for outcomes describing episodic or acute changes, which are inherently short-term. Long-term effects are not fully established, and there is limited information for long-term outcomes or durability of effect beyond the single use. The body of evidence is limited by its focus on acute or disruptive episodes and single-use administration, and comparative evidence appears to be limited for a direct assessment against all modern, systemic laxative options.

Key Studies & References

  1. Microlax (Sodium Citrate and Sodium Lauryl Sulfoacetate) Drug Label Information
  2. Anatomical Therapeutic Chemical (ATC) Classification System - A06AG11

Frequently Asked Questions (FAQ)

Common questions about Micralax (FAQ)

Q: Is Micralax safe to use during pregnancy?

According to official product information, occasional use of this medicine during pregnancy is described as generally acceptable. This is because the product works locally in the rectum and has minimal systemic absorption, meaning very little of the active ingredients enter the bloodstream.

Q: Can people who are breastfeeding use Micralax?

Regulatory labeling indicates that occasional use during lactation is described as acceptable. This is based on the understanding that the product acts locally and is not significantly absorbed into the body or transferred into breast milk.

Q: What kind of studies have been performed on Micralax?

Regulatory documents indicate that the medicine has been examined in various research contexts, including clinical trials and comparative studies. These studies focused on outcomes such as the time required for the product to work, patient comfort levels, and its effectiveness when used for local bowel preparation before certain procedures.

Q: Is the onset of action guaranteed to be within the time frame stated in the leaflet?

Official instructions state that the medicine is generally expected to start working within 5 to 30 minutes after application. However, as with most medications, a specific outcome time cannot be guaranteed for every individual.

Q: What happens if Micralax doesn't work after the first use?

Regulatory patient information suggests that if constipation continues after a few days of treatment or if you experience no improvement in your symptoms, the user seek guidance from a doctor.

Q: What is Micralax actually used for?

Micralax is formally indicated for the symptomatic local relief of occasional constipation and is also approved for use in localized bowel preparation before certain medical procedures, such as X-ray or endoscopic examinations of the rectum.

Q: Is Micralax the same thing as a traditional enema?

The medicine is classified as a micro-enema. This classification distinguishes it from traditional enemas due to its small, single-dose volume and its focused, local action in the lower bowel, which is intended to provide easy and gentle bowel emptying.

Q: Why is Micralax packaged in such a small tube?

The micro-enema is packaged in a small, 5 mL unit dose tube because it is specifically designed for local action. Only a small volume of the solution is required to be administered directly into the lower bowel to achieve the intended physical effect on the stool.

Q: Does Micralax cause stomach cramps or pain?

Official reports of adverse events list abdominal pain and anorectal discomfort as possible side effects. Rectal or anal discomfort is often noted due to the method of administration and local action.

Q: Can Micralax be used by elderly people?

Official patient information indicates the medicine is included in the populations indicated for the treatment of occasional constipation.

Q: Is Micralax known to interact with birth control pills?

Since this product acts locally and is minimally absorbed into the body, official labeling states there are no documented systemic pharmacokinetic interactions with it. This refers to systemic effects, which are not documented for this localized product.

Q: Do you need a prescription to buy Micralax?

In relevant jurisdictions, the regulatory classification indicates that it is an Over-The-Counter (OTC) medicine. This means it is typically available for purchase without requiring a prescription.

Q: What is the recommended age limit for using Micralax?

The medicine is approved for use in adults and children aged 3 years and over. There are specific administration instructions for children under 3 years old, which defines the age range for appropriate use.

Q: Are there any reported interactions between Micralax and alcohol?

Official government labels state that there are no restrictions or warnings regarding interactions with food or alcohol when using this product.

Q: Is it possible to become dependent on Micralax if I use it too often?

Official safety warnings explicitly state that prolonged or continuous use of laxatives is generally undesirable and may carry the risk of dependence and local irritation. The product is described as intended for occasional, short-term relief.

Q: How does the mechanism of Micralax differ from a bowel irritant?

The medicine’s mechanism is described as physico-chemical, involving wetting and osmotic action to soften the stool, followed by mechanical stimulation. This differs from an irritant laxative, which works by causing direct muscle contraction in the bowel wall.

Q: Does Micralax work by drawing water into the bowel?

Yes. One of the active ingredients, Sodium Citrate, functions as an osmotic agent. Its role is to help draw water into the lower bowels or release water bound in the stool, leading to softening and easier passage.

Q: Can people with kidney problems use Micralax?

Regulatory information states that caution is advised in patients with renal impairment (kidney problems). This is because the sodium citrate component is primarily excreted by the kidneys.

Q: What happens to the ingredients of Micralax after they have done their job?

The active ingredients are designed to act locally on the stool in the rectum, providing rapid effect. Once they have softened the stool, they are subsequently eliminated with the modified fecal matter during the bowel evacuation.

Q: Why do doctors sometimes recommend Micralax over other options?

Regulatory text notes that the medicine is optimized for its non-systemic approach and provides prompt and comfortable bowel evacuation due to its local application. These characteristics are factors that can influence clinical preference.

Q: What is the risk of electrolyte imbalance with Micralax?

Due to its minimal systemic absorption, the risk is considered minimal when used as directed. However, regulatory warnings exist about the potential for electrolyte disturbances, particularly in cases of overdose or chronic misuse.

Q: Does Micralax cause dehydration?

When used correctly, the product is intended to be locally acting. However, regulatory information notes that using too much of the medicine (overdose or overuse) may lead to loss of fluid or diarrhea.

Q: Is it normal for some of the gel to come back out immediately?

The administration instructions require the user to withdraw the nozzle while keeping the tube squeezed tightly. This procedural step is specifically designed to help ensure retention of the dose.

Q: Can Micralax be used for general bowel cleansing?

Official indications support its use for localized clearance or preparation for examination of the rectum (such as rectoscopy), but not for general bowel cleansing procedures.

Q: Why do people use Micralax before a medical procedure?

Official indications include its use for bowel preparation before certain medical procedures, such as X-ray examinations or rectoscopy, where localized clearance is needed.

Q: Is Micralax an osmotic laxative?

The medicine is classified within the group of laxatives and the mechanism states that the active component Sodium Citrate acts as an osmotic agent. Therefore, osmotic action is a key part of its function.

Q: Is it true that Micralax works faster than oral laxatives?

Official descriptions highlight that the product is recognized for achieving its effect rapidly. This rapid action is attributed to its local application, as opposed to oral laxatives which must travel through the digestive system.

Q: What is the main chemical role of the active ingredients in the rectum?

The two active ingredients work together with a dual chemical role. One acts as a peptising agent, releasing bound water from the stool, while the other acts as a surfactant or wetting agent, allowing the solution to penetrate the hardened stool quickly.

Q: Is it normal to pass some liquid stool after using Micralax?

The medicine's mechanism of action involves the softening and liquefaction of the stool to ease its passage. The mechanism of action results in the evacuation of modified and softer fecal matter.

Q: Can Micralax affect how other medications are absorbed?

Official labeling states there are no documented pharmacokinetic interactions, which is consistent with its non-systemic use. No restrictions are listed regarding co-administered rectal medications, but it is a localized product.

Q: Is there a maximum number of times Micralax can be used in a month?

Official information advises against prolonged or continuous use and specifies a formal limit of not more than 6 consecutive days of use. It is intended for occasional relief, not regular, daily treatment.

Q: Does Micralax contain gluten or lactose?

Official regulatory documents list the excipients (inactive ingredients) contained in the product, such as Sorbitol and Glycerol. These documents do not list lactose or gluten as components of the formulation.

How should Micralax be stored and disposed of?

Micralax micro-enemas must be stored in a cool, dry place, away from excessive heat and direct sunlight. It is essential to keep this medicine, like all medications, out of the sight and reach of children and pets to prevent accidental ingestion. Do not store Micralax in a bathroom or near a sink, as excessive moisture can affect the product.

Ensure that the medication is not used past the expiration date printed on the packaging.

Storage and Disposal Guidelines

Action Instruction
Storage Temperature Store below 25 C or 30 C, as indicated on the package.
Disposal of Unused/Expired Unused or expired tubes should be returned to a pharmacist or local drug take-back program.
Disposal of Empty Tubes Empty, used tubes can generally be disposed of safely with household garbage.

Do not dispose of this medicine by flushing it down a toilet or pouring it into a drain, as this can contaminate the wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Micralax found in:

A-Z Index: